Revance Q4 product revenue $58.5M (+28%); guides 2024 at least $280M

Revance Therapeutics, Inc.

2023-FY EPS reported -$3.83 revenue$234,040,000

Q4 product revenue $58.5M (DAXXIFY $24M, RHA $34.5M); full year product $212.7M (+80% YoY).
2024 product revenue guidance at least $280M; DAXXIFY cervical dystonia launch mid-year.
GAAP net loss FY 2023 $324M; Adjusted EBITDA loss $160.1M; cash $253.9M as of Dec 31.
President Dustin Sjuts steps down effective March 31; separation includes 18 months base salary.
OPUL payments business exit by Q1 2024, generating ~$20M annual savings.

item 1.01 item 2.02 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Dustin Sjuts

President

Revance Therapeutics, Inc.

Effective: 2024-03-31
Filed: February 28, 2024, 6:59 PM ET

On January 8, 2024, the Company announced that Mr. Sjuts is stepping down from his current position as President of the Company, effective as of March 31, 2024.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Revance Therapeutics, Inc. updated its 2024 guidance (initiated).

Period: 2024
Guidance: initiated
Result: guidance update

Exact text from the filing

2024 product revenue guidance of at least $280 million, supporting blockbuster potential in U.S. aesthetics.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Revance Therapeutics, Inc. updated its the fourth quarter and full year ended December 31, 2023 guidance (initiated).

Period: the fourth quarter and full year ended December 31, 2023
Guidance: initiated
Result: reported results

Exact text from the filing

On February 28, 2024, the Company issued a press release announcing its financial results for the three months and fiscal year ended December 31, 2023 and the Company's financial outlook for 2024.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Dustin Sjuts departed as President at Revance Therapeutics, Inc..

Action: stepping down
Role: President

Exact text from the filing

On January 8, 2024, the Company announced that Mr. Sjuts is stepping down from his current position as President of the Company, effective as of March 31, 2024.

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Revance Therapeutics, Inc. amended Amendment No. 2 to the Technology Transfer, Validation and Commercial Fill/Finish Services Agreement with Ajinomoto Althea, Inc. dba Ajinmoto Bio-Pharma Services (effective 2024-02-26).

Action: amendment
Agreement: supply
Counterparty: Ajinomoto Althea, Inc. dba Ajinmoto Bio-Pharma Services
Effective: 2024-02-26

Exact text from the filing

On February 26, 2024, Revance Therapeutics, Inc. (the “Company”) and Ajinomoto Althea, Inc. dba Ajinmoto Bio-Pharma Services, a contract development and manufacturing organization (“ABPS”), entered into Amendment No. 2 to the Technology Transfer, Validation and Commercial Fill/Finish Services Agreement (the “Amendment”)

View on SEC.gov

326 earnings releases filed in the last 30 days. Browse all earnings releases →

Source: SEC EDGAR

accession 0001479290-24-000034

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.